## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) A percutaneously absorbable preparation comprising sodium <u>dichlorofenac diclofenac</u> and ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold mole based on the sodium <u>diclofenac dichlorofenac</u>.
  - 2. (Cancelled).
  - 3. (Cancelled)
- 4. (Previously presented) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is a nonaqueous preparation.
- 5. (Currently Amended) The percutaneously absorbable preparation according to claim 1, wherein the percutaneously absorbable preparation is <u>a patch</u> <u>comprising</u> a matrix, <u>type patch</u> or an ointment.
  - 6. (Cancelled)
- 7. (Currently amended) The percutaneously absorbable preparation according to claim 1, wherein the ammonium chloride is combined at the range of from 0.5 to 7 fold mole based on the sodium dichlorofenae diclofenae.

Y. Takada, et al. U.S.S.N. 10/030,825 Page 4

- 8. (Currently Amended) The percutaneously absorbable preparation according to any one of claims 1, 4-5 or 7, which is a matrix-type-percutaneously absorbable matrix preparation, wherein the sodium dichlorofenac diclofenac and the ammonium chloride are contained in an adhesive basis layer.
- 9. (Currently amended) The matrix-type-percutaneously absorbable preparation according to claim 8, wherein the adhesive basis layer is composed of one or more than two of stylene\_styrene-isoprene-styrene\_stylene\_block copolymer, polyisobutylene, and acrylic adhesive.
- 10. (Currently Amended) A percutaneous absorption accelerating composition of sodium <u>diclofenac dichlorofenac</u>, which contains ammonium chloride, wherein the ammonium chloride is blended at the range of from 0.5 to 10 fold mole based on the sodium diclofenac <u>dichlorofenac</u>.

11. - 12. (Cancelled)